ABEONA THERAPEUTICS INC. (ABEO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 25.52M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 8.40M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $25.52M | $8.40M | (m) |
| 2026-03-31 | (m) | $14.54M | (m) | (m) |
| 2025-12-31 | (m) | $5.82M | $1.53M | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.50M | (m) | (m) |
| 2023-09-30 | (m) | $3.57M | (m) | (m) |
| 2023-06-30 | (m) | $3.57M | (m) | (m) |
| 2022-12-31 | (m) | $1.41M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.00M | (m) | (m) |
| 2020-12-31 | (m) | $10.00M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.19M | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.00M | (m) | (m) |
| 2018-09-30 | (m) | $5.34M | (m) | (m) |
| 2018-06-30 | (m) | $1.24M | (m) | (m) |
| 2018-03-31 | (m) | $3.25M | (m) | (m) |
| 2017-12-31 | (m) | $837.00K | (m) | (m) |
| 2017-09-30 | (m) | $878.00K | (m) | (m) |
| 2017-06-30 | (m) | $843.00K | (m) | (m) |
| 2017-03-31 | (m) | $840.00K | (m) | (m) |
| 2016-12-31 | (m) | $889.00K | (m) | (m) |
| 2016-09-30 | (m) | $848.00K | (m) | (m) |
| 2016-06-30 | (m) | $949.00K | (m) | (m) |
| 2016-03-31 | (m) | $1.02M | (m) | (m) |
| 2015-12-31 | (m) | $1.04M | (m) | (m) |
| 2015-09-30 | (m) | $1.06M | (m) | (m) |
| 2015-06-30 | (m) | $1.01M | (m) | (m) |
| 2015-03-31 | (m) | $975.00K | (m) | (m) |
| 2014-12-31 | (m) | $925.00K | (m) | (m) |
| 2014-09-30 | (m) | $853.00K | (m) | (m) |
| 2014-06-30 | (m) | $806.00K | (m) | (m) |
| 2014-03-31 | (m) | $1.03M | (m) | (m) |
| 2013-12-31 | (m) | $2.04M | (m) | (m) |
| 2013-09-30 | (m) | $2.89M | (m) | (m) |
| 2013-06-30 | (m) | $3.57M | (m) | (m) |
| 2013-03-31 | (m) | $3.79M | (m) | (m) |
| 2012-12-31 | (m) | $4.40M | (m) | (m) |
| 2012-09-30 | (m) | $3.90M | (m) | (m) |
| 2012-06-30 | (m) | $4.08M | (m) | (m) |
| 2012-03-31 | (m) | $3.55M | (m) | (m) |
| 2011-12-31 | (m) | $1.85M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $481.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |